Medical Management of Recurrence References:
1. Cornely, O.A., et al., Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis, 2012. 55 Suppl 2: p. S154-61.
2. McFarland, L.V., G.W. Elmer, and C.M. Surawicz, Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol, 2002. 97(7): p. 1769-75.
3. Sirbu, B.D., et al., Vancomycin Taper and Pulsed Regimen with careful Follow up for Patients with Recurrent Clostridium difficile Infection. Clin Infect Dis, 2017.
4. Garey, K.W., et al., Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol, 2009. 43(1): p. 91-3.
5. Soriano, M.M., et al., Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies. Open Forum Infect Dis, 2014. 1(2): p. ofu069.
6. Wilcox, M.H., et al., Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med, 2017. 376(4): p. 305-317.
7. Gerding, D.N., et al., Bezlotoxumab for prevention of recurrent C. difficile infection in patients at increased risk for recurrence. Clin Infect Dis, 2018.
DISCLAIMER: The information contained herein should not be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This website may not cover all possible drug interactions or all FDA warnings or alerts. Each individual clinical circumstance is unique and requires a licensed clinical provider to assess properly. Please check with a physician or a licensed medical practitioner if you have health questions or concerns about interactions or go to the FDA for a comprehensive list of FDA warnings. Although everythingcdifficile attempts to provide accurate and up-to-date information, no guarantee is made to that effect.